DC Chemicals

All products / DC20111

Kira8
CAT. NO. DC20111

Kira8

Pack sizes and prices

Pack sizePrice
100 mg$750 USDRequest a quote / confirm availability →
250 mg$1,350 USDRequest a quote / confirm availability →
1 g$2,700 USDRequest a quote / confirm availability →

Confirm stock, lead time, shipping and final quotation with our team.

Product overview

In Vitro KIRA8 blocks IRE1α oligomerization, and potently inhibits IRE1α RNase activity against XBP1 and Ins2 RNAs. KIRA8 more potently reduces IRE1α-driven apoptosis in INS-1 cells than KIRA6 and also reverses XBP1 splicing promoted by GNF-2. In Vivo Kira8 efficaciously reverses established diabetes in NOD mice by sparing β-cells and preserving their physiological function. KIRA8 is first tested in 3-week-old male pre-diabetic Akita mice by i.p. daily dosing of 50 mg/kg, whereupon significant reduction of hyperglycemia became apparent over several weeks. Then KIRA8 (50 mg/kg) is tested in the complex NOD. Showing target engagement, one week treatment of pre-diabetic NODs with KIRA8 leads to significant reductions in islet XBP1 splicing and TXNIP mRNAs, and preserved Ins1/Ins2, BiP and MANF mRNAs.

For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.

Identity and specifications

Catalog numberDC20111
Product nameKira8
CAS1630086-20-2
Molecular formulaC31H29ClN6O3S
Molecular weight601.12
Purity>98%
SMILESCc1ccc2c(NS(=O)(=O)c3ccccc3Cl)cccc2c1Oc1ncccc1-c1ccnc(N[C@H]2CCCNC2)n1

Source-listed specifications; the batch COA applies.

Source and product documents

The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.

DC Chemicals — Kira8 (DC20111)

Related research products

Browse newly added products